In the preclinical model of CRC, specific inactivation of IL-1R in cell types other than myeloid cells has confirmed that IL-1 signaling promotes proliferation and survival of neoplastic cells and drives both Th17 differentiation and production of pro-tumorigenic cytokines (IL-17 and IL-22) [88]. This evidence concerns the gene IL1R1 and colorectal carcinoma.